LAUSR

Background Latamoxef, a new broad-spectrum oxac-ephem antibiotic, was used off-label in neonates. The present study aims to evaluate pharmacokinetics of latamoxef in neonates and establish appropriate dosing regimen. Methods Blood samples were collected from neonates treated with latamoxef and concentrations were quan-tified by HPLC-UV. Population pharmacokinetic analysis was performed using NONMEM software. Results A total of 42 neonates were recruited. A one-compartment model with first-order elimination showed the best fit with the data. Current weight and postmenstrual age were identified as significant covari-ates on clearance. Current weight was identified as a sig-nificant covariate on volume of distribution. The reliability and stability of the population pharmacokinetic model was evaluated by bootstrap and normalised predictive distribution error. Conclusion The population pharmacokinetics of lata-moxef was evaluated in neonates and an optimal dosing regimen was established.